An investigation of proportion designs based on a molecularly targeted endpoint

Seung Ho Kang, Sangmee Lee, Chul W. Ahn

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Most phase 1 clinical trials for anticancer agents base dose escalation on toxicity and are employed to find the maximum tolerated dose. Recently, Hunsberger et al. (Statistics in Medicine 2005; 24: 2171-2181) proposed proportion designs that are useful for molecularly targeted agents, because these new agents do not yield severe toxicity. The aim of the proportion designs is to find a dose to produce a specific high response rate. We generalize the proportion designs and derive the exact formulas of key statistical properties of the generalized proportion designs. Using the exact formulas, we compute the expected response rate at the recommended dose and the expected number of patients to finish the trials. Based on the numeric results, we recommend six generalized proportion designs.

Original languageEnglish (US)
Pages (from-to)527-535
Number of pages9
JournalDrug Information Journal
Volume42
Issue number6
StatePublished - 2008

Fingerprint

Clinical Trials, Phase I
Maximum Tolerated Dose
Antineoplastic Agents
Medicine
Toxicity
Statistics

Keywords

  • Cancer
  • Exact formula
  • Phase 1 trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (nursing)
  • Drug guides

Cite this

An investigation of proportion designs based on a molecularly targeted endpoint. / Kang, Seung Ho; Lee, Sangmee; Ahn, Chul W.

In: Drug Information Journal, Vol. 42, No. 6, 2008, p. 527-535.

Research output: Contribution to journalArticle

@article{3211bb302fbf465aa62369bc0a7446cf,
title = "An investigation of proportion designs based on a molecularly targeted endpoint",
abstract = "Most phase 1 clinical trials for anticancer agents base dose escalation on toxicity and are employed to find the maximum tolerated dose. Recently, Hunsberger et al. (Statistics in Medicine 2005; 24: 2171-2181) proposed proportion designs that are useful for molecularly targeted agents, because these new agents do not yield severe toxicity. The aim of the proportion designs is to find a dose to produce a specific high response rate. We generalize the proportion designs and derive the exact formulas of key statistical properties of the generalized proportion designs. Using the exact formulas, we compute the expected response rate at the recommended dose and the expected number of patients to finish the trials. Based on the numeric results, we recommend six generalized proportion designs.",
keywords = "Cancer, Exact formula, Phase 1 trials",
author = "Kang, {Seung Ho} and Sangmee Lee and Ahn, {Chul W.}",
year = "2008",
language = "English (US)",
volume = "42",
pages = "527--535",
journal = "Drug Information Journal",
issn = "0092-8615",
publisher = "Drug Information Association",
number = "6",

}

TY - JOUR

T1 - An investigation of proportion designs based on a molecularly targeted endpoint

AU - Kang, Seung Ho

AU - Lee, Sangmee

AU - Ahn, Chul W.

PY - 2008

Y1 - 2008

N2 - Most phase 1 clinical trials for anticancer agents base dose escalation on toxicity and are employed to find the maximum tolerated dose. Recently, Hunsberger et al. (Statistics in Medicine 2005; 24: 2171-2181) proposed proportion designs that are useful for molecularly targeted agents, because these new agents do not yield severe toxicity. The aim of the proportion designs is to find a dose to produce a specific high response rate. We generalize the proportion designs and derive the exact formulas of key statistical properties of the generalized proportion designs. Using the exact formulas, we compute the expected response rate at the recommended dose and the expected number of patients to finish the trials. Based on the numeric results, we recommend six generalized proportion designs.

AB - Most phase 1 clinical trials for anticancer agents base dose escalation on toxicity and are employed to find the maximum tolerated dose. Recently, Hunsberger et al. (Statistics in Medicine 2005; 24: 2171-2181) proposed proportion designs that are useful for molecularly targeted agents, because these new agents do not yield severe toxicity. The aim of the proportion designs is to find a dose to produce a specific high response rate. We generalize the proportion designs and derive the exact formulas of key statistical properties of the generalized proportion designs. Using the exact formulas, we compute the expected response rate at the recommended dose and the expected number of patients to finish the trials. Based on the numeric results, we recommend six generalized proportion designs.

KW - Cancer

KW - Exact formula

KW - Phase 1 trials

UR - http://www.scopus.com/inward/record.url?scp=57449108286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449108286&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:57449108286

VL - 42

SP - 527

EP - 535

JO - Drug Information Journal

JF - Drug Information Journal

SN - 0092-8615

IS - 6

ER -